 Today I have the pleasure of speaking with Anthony Dirk. It's from FSD pharma. How are you today, Anthony? Great. Thank you What such a pleasure to catch up with you first of all I I see that you're the CEO and you're running the ship over at FSD pharma any time you put your name on anything That's exciting to shareholders. Tell me how that's going Thank you. It's it's been a transition and It's it's it's something that you know I want to do because I feel that is one of the co-founders of the company that we wanted to put the company on a track and add to our biotechnology pipeline and so with our lucid acquisition announced yesterday We have done that and so we have now increased in my opinion Some very exciting molecules to add to our drug development pipeline Of course, we're doing this in interview because I want to know more. I saw the headline FSD pharma announces closing of lucid Psychoceuticals acquisition and here's what where it gets really interesting for those of you out there that missed the huge news It says that lucid adds potential for neurodegenerative disease treatments and mental health in a novel way Where do we start here? Anthony give us a Give us an update please and congratulations on this acquisition. Thank you So what it means is that there are two compounds that lucid brings to the FSD pipeline the first is an exclusive worldwide patent To a family of molecules from the university health network The university health network is the largest health research organization in all of North America and What's unique about it or what really excites us about it is that the target is everything to do with MS treatments today has been around the immune system and The way lucid is it and the way the EHM Patented this molecule is that this is a totally different and unique approach. It's not targeting the immune system it's targeting another area of the brain and central nervous system and What we want to do is that sometimes when you have people that have MS and it is a terrible disease and there is no cure for MS Often people can lose their function and their muscle and we think this has the potential To give them back some of the the the loss So if someone ends up in a wheelchair, you know We hope that this will actually be able to to reverse some of that type of damage caused by MS The second is a really unique psychedelic compound Which is not your normal compounds that are psychedelics that people talk about. So this is not LSD This is not psilocybin. This is not ketamine. This is not MDMA. This is not DMT This is not Ibogaine and that's what really excites us about it Okay, but there's a lot of things that excite me about it But let let's start with the benefit of the acquisition of some huge Intellectual IP and Dr. Kotra that came with this deal. Can you tell us a little bit more about how he will be leading this team? Absolutely. So yeah, Dr. Kotra has has an incredible background He's been part of the university health care a network and he's been part of the University of Toronto and he's He's he's exactly I think what we needed. We needed to complement our existing team with world-class Researchers and doctors Network and so that's what he brings to the table for us today We don't often get someone with your financial background Actually in the role as CEO and the the whole deal that was put together was kind of fascinating to me You your shares outstanding are still, you know, you only have 40 million shares outstanding night Did I read that properly or correct me here? Yes? So yeah So it is just over 40 million shares outstanding after the acquisition. We were able to make the acquisition with 4.5 million shares of Huge what's more exciting? Also, I think in from our opinion is you know that as of June 30th 2021 we had over 54 million 100,000 US dollars worth of current assets and And we have no debt today. So we're in a very very unique financial shape to be able to Implement and in the work now from the Lucid acquisition Well, I'll tell you as an investor you seem to be hitting all the fundamentals out of the ballpark Anthony websites fantastic everyone out an investor Intel if you want to learn more they have an incredible Library on their website. Thank you so much for joining us with FSD pharma. Thank you, Anthony. Thank you